Product
KIO-301
1 clinical trial
2 indications
Indication
Retinitis PigmentosaIndication
ChoroideremiaClinical trial
A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)Status: Recruiting, Estimated PCD: 2024-12-01